Glythera Ltd. Press releases
1 - 3 of 3 Press Releases
Oct 04, 2010
Second tranche of seed investment triggered
Sep 06, 2010
The FDA is to assess the feasibility of Glythera technology in developing antigenic glycoproteins as synthetic conjugate vaccines.
Aug 02, 2010
Glythera to provide novel technology to aid the development of pneumococcal conjugate vaccines